Richard Zhang

Richard Zhang, PhD, is a strategic biometrics leader with over 20 years of experience in the pharmaceutical industry, specializing in regulatory strategy and AI innovation within the fields of Neuroscience, Rare Disease, Pain, and Rheumatology. Previously, they held various positions at Pfizer, leading teams responsible for significant developments including XELJANZ and ARICEPT, and managing biometrics operations for global clinical programs. Currently, Richard oversees statisticians in support of regulatory submissions and medical affairs in multiple rare disease areas. Active in regulatory data policy and AI adoption, Richard continues to advance statistical excellence and drive innovation within the industry.